Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 6/20 | 0.71 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | CTSL | P07711 | 3/20 | 0.61 |
| ▸ | CTSS | P25774 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | ACE | P12821 | 2/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17244326 | 1.00 | HPGDS (0.71) | HPGDSCA1CA12CA9CTSL | |
| SCHEMBL11425335 | 0.91 | HPGDS (0.68) | HPGDSCA1CA12CA9CTSL | |
| SCHEMBL11781402 | 0.91 | HPGDS (0.68) | HPGDSCA1CA12CA9CTSL | |
| SCHEMBL4684065 | 0.90 | HPGDS (0.65) | HPGDSCA1CA12CA9CTSL | |
| SCHEMBL27002688 | 0.90 | HPGDS (0.65) | HPGDSCA1CA12CA9CTSL | |
| SCHEMBL2105972 | 0.90 | HPGDS (0.65) | HPGDSCA1CA12CA9CTSL | |
| SCHEMBL12320657 | 0.90 | HPGDS (0.64) | HPGDSCA1CA12CA9CA2 | |
| SCHEMBL27695921 | 0.90 | HPGDS (0.65) | HPGDSCA1CA12CA9CTSL | |
| Hydrochloric Acid SCHEMBL7275137 | 0.88 | HPGDS (0.67) | HPGDSCA1CA12CA9CA2 | |
| SCHEMBL8443478 | 0.87 | CTSL (0.62) | HPGDSCA1CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068405-B1 | PYRROLO [1,2,F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2019-05-01 | — | — | EP | claimed |
| EP-4419513-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12384800-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-07-31 | — | — | US | disclosed |
| EP-4419513-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2024-08-28 | — | — | EP | disclosed |
| EP-4403042-A2 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | Mars, Incorporated (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-3229612-B1 | USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-118139851-A | Antitumor compounds | 法马马有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| US-10538535-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2020-01-21 | — | — | US | disclosed |
| US-10442820-B2 | — | — | 2019-10-15 | — | — | US | disclosed |
| US-20190021380-A1 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2019-01-24 | — | — | US | disclosed |
| US-20180312529-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2018-11-01 | — | — | US | disclosed |
| WO-2018197663-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2018-11-01 | — | — | WO | disclosed |
| US-20180168208-A1 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180168208-A1 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2018-06-21 | — | — | US | disclosed |
| CN-102209532-B | Method for reducing small, dense LDL particles | METABOLEX INC | 2015-07-22 | — | — | CN | disclosed |
| CN-101184726-B | 2-arylpropionic acid derivatives and pharmaceutical compositions containing them | DOMPE PHA R MA SPA RES & MFG | 2012-05-30 | — | — | CN | disclosed |
| CN-101184726-A | 2-arylpropionic acid derivatives and pharmaceutical compositions containing them | DOMPE PHA R MA SPA RES & MFG (IT) | 2008-05-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384800-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | HPGDS 169/4885CA1 567/4885CA12 277/4885 |
| US-10538535-B2 | Antitumoral compounds | TP53, RB1, XPOT | HPGDS 2407/4885CA1 1866/4885CA12 1191/4885 |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | MCL1, XPOT, GZMB | HPGDS 1144/4885CA1 945/4885CA12 305/4885 |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | HPGDS 942/4885CA1 2782/4885CA12 1331/4885 |
| US-10442820-B2 | — | RPS4X, RPS4Y1, XPOT | HPGDS 2415/4885CA1 2834/4885CA12 1419/4885 |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | TP53, TOP1, MCL1 | HPGDS 169/4885CA1 567/4885CA12 277/4885 |
| US-20180312529-A1 | Antitumoral Compounds | TP53, RB1, XPOT | HPGDS 2407/4885CA1 1866/4885CA12 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.